Accelerated Pharma News

|||||||||| cisplatin / Generic mfg.
Journal: From Basics of Coordination Chemistry to Understanding Cisplatin-analogue Pt Drugs. (Pubmed Central) - Aug 10, 2023
In the development of platinum complexes, strong anti-cancer drug activity, low toxicity, and resistance can be obtained by the application of polynuclear platinum agents, complexes with targeted activity, and nanoparticle formulations. Electronic structure, stereochemical, and thermodynamic properties are essential for understanding the reaction mechanism of platinum complexes.

|||||||||| Aqupla (nedaplatin) / Simcere, picoplatin (AMD 473) / Accelerated Pharma
Journal: Thermosensitive Liposomes Encapsulating Nedaplatin and Picoplatin Demonstrate Enhanced Cytotoxicity against Breast Cancer Cells. (Pubmed Central) - Nov 29, 2022
The cytotoxicity of ND-TSL, p-SC4-ND-TSL, and P-TSL at 40 °C was approximately twice those observed at 37 °C. This study suggests that TSL is a promising nanoplatform for the temperature-triggered release of platinum-based drugs into cancer cells.

|||||||||| picoplatin (AMD 473) / Accelerated Pharma
Journal: An unexpected in-solution instability of diiodido analogue of picoplatin complicates its biological characterization. (Pubmed Central) - Nov 10, 2021
Complex cis-[PtI2(NH3)(pic)] (1; pic = 2-methylpyridine), a diiodido analogue of clinically studied picoplatin (2), is unstable in solution, which is intriguingly connected with the release of its pic ligand. This observation complicates the biological testing of e.g. cytotoxicity in human cancer cells for 1.

|||||||||| picoplatin (AMD 473) / Accelerated Pharma
Review, Journal: Anticancer platinum(II) complexes bearing N-heterocycle rings. (Pubmed Central) - Sep 13, 2020
This review deals in particular with both the bifunctional and monofunctional platinum drugs, not only in dichloride platinum(II) complexes, but also in recent advances in modern platinum structures, i.e. cationic ones. Both the in vitro and in vivo studies of these anticancer agents are taken into account, with a special consideration for aggressive and orphan in treatment tumors.

|||||||||| picoplatin (AMD 473) / Poniard
Journal: A computational study of PAMAM dendrimer interaction with trans isomer of picoplatin anticancer drug. (Pubmed Central) - Sep 20, 2019
The PAMAM-AMD complexes have shown a significant improvement of structural and electronic properties according to the results obtained from different arrangement of PAMAM G0-AMD complexes; a [G0-AMD (Cl-1)] complex is the preferred adsorption arrangement. As a result, it seems that the zero generation PAMAM dendrimer being combined with the AMD drug is suitable for use in drug delivery.

||||||||||  picoplatin (AMD 473) / Accelerated Pharma
Trial completion:  Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer (clinicaltrials.gov) -  Feb 22, 2014
P2, N=75, Completed,  Sponsor: Poniard Pharmaceuticals
As a result, it seems that the zero generation PAMAM dendrimer being combined with the AMD drug is suitable for use in drug delivery. No longer recruiting --> Completed

||||||||||  picoplatin (AMD 473) / Accelerated Pharma
Trial completion, Metastases:  ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) -  Jun 16, 2013
P1, N=0, Completed,  Sponsor: Memorial Sloan-Kettering Cancer Center
No longer recruiting --> Completed Active, not recruiting --> Completed



	Diseases Companies Products Productz Mechanisms of Action Sites